Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Plus Erlotinib for Rash-Positive Metastatic Pancreatic Cancer
NCT01729481Phase 2Unknown
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Jul 2012
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in pancreatic adenocarcinoma (PDAC), sponsored by Ludwig Maximilian University of Munich. Status: unknown.
02
Drugs
erlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01729481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01729481.